Another research group utilized engineered bone-marrow-derived myeloid cells releasing interleukin-2 (GEMys-IL2) in mice with low-grade gliomas that readily crossed the BBB and entered the TME to stimulate the immune cell response [48]. The gene discussed is IL2; the disease is central nervous system cancer.